Erasca is a clinical-stage biopharmaceutical company developing precision oncology therapies aimed at cancers driven by the RAS/MAPK signaling pathway. Its pipeline centers on targeted small-molecule programs designed to address mutations and resistance mechanisms common in hard-to-treat solid tumors. The company focuses on scientifically defined patient populations rather than broad chemotherapy approaches.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -31 | — |
| Q2 2025 | 0 | — | -33.9 | — |
| Q3 2025 | 0 | — | -30.6 | — |
| Q4 2025 | 0 | — | -29.1 | — |
| Q1 2026 | 0 | — | -183.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Camtek Ltd. (CAMT), Travere Therapeutics, Inc. (TVTX), Credit Acceptance Corporation (CACC), Netskope, Inc. (NTSK), Kiniksa Pharmaceuticals International, plc (KNSA), Oruka Therapeutics, Inc. (ORKA)